Company Analysis
Sign in

BioNTech SE (BNTX)

Nasdaq: BNTX · Biological Products, (No Diagnostic Substances) · Mainz, DE · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.9
◀ Past 6.8● Present 5.8▶ Future 5.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

301 patents granted to the 22 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioNTech SE’s names, not what it holds today.

Patents granted
301
300 utility, 1 design, 1976 to Dec 31, 2025
Granted in 2025
50
Against 39 in 2024 and 39 in 2023
Applications published
651
75 of them in 2025
Names they are printed under
22
a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals131
Biotechnology34
Computer technology8
Organic fine chemistry5
Medical technology5
Measurement4
Analysis of biological materials2
Furniture, games1
IT methods for management1
Chemical engineering1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name22 counted
CureVac AG a subsidiary
DE, as the owner printed on each patent
101 granted
222 published
BioNTech SE its own name
named as the applicant on its applications, in DE
0 granted
186 published
CureVac SE a subsidiary
DE, as the owner printed on each patent
59 granted
77 published
BioNTech SE its own name
DE, as the owner printed on each patent
66 granted
6 published
CureVac AG a subsidiary
named as the applicant on its applications, in DE
0 granted
63 published
BioNTech AG its own name
DE, as the owner printed on each patent. 2 more under the same name are not counted (printed in KR, printed in TW)
36 granted
15 published
CureVac Manufacturing GmbH a subsidiary
DE, as the owner printed on each patent
10 granted
15 published
BioNTech US Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
23 published
BIONTECH CELL & GENE THERAPIES GMBH a subsidiary
named as the applicant on its applications, in DE
0 granted
20 published
BIONTECH US INC. a subsidiary
US, as the owner printed on each patent
9 granted
0 published
BioNTech Cell & Gene Therapies GmbH a subsidiary
DE, as the owner printed on each patent
7 granted
2 published
InstaDeep Ltd a subsidiary
named as the applicant on its applications, in GB
0 granted
7 published
BioNTech Research and Development, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
Insta Deep Ltd a subsidiary
GB, as the owner printed on each patent
4 granted
0 published
BioNTech Delivery Technologies GmbH a subsidiary
DE, as the owner printed on each patent
2 granted
1 published
BioNTech Diagnostics GmbH a subsidiary
DE, as the owner printed on each patent
3 granted
0 published
BioNTech Diagnostics GmbH a subsidiary
named as the applicant on its applications, in DE
0 granted
3 published
CureVac Netherlands B.V. a subsidiary
named as the applicant on its applications, in NL
0 granted
3 published
JPT Peptide Technologies GmbH a subsidiary
named as the applicant on its applications, in DE
0 granted
3 published
CureVac Netherlands B.V. a subsidiary
NL, as the owner printed on each patent
2 granted
0 published
JPT Peptide Technologies GmbH a subsidiary
DE, as the owner printed on each patent
1 granted
1 published
BIONTECH RESEARCH AND DEVELOPMENT, INC. a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
1 granted
0 published
Names not counted (2)
Biotheus
Most of its patents print CN; this name counts in KY. 0 granted and 21 published under it are not counted.
Biotheus
Most of its patents print CN; this name counts in KY. 2 granted and 3 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,308Influenza mRNA vaccinesPharmaceuticalsCureVac SE
Dec 16, 202512,496,335Zika virus vaccinePharmaceuticalsCureVac SE
Dec 9, 202512,492,425Methods for RNA analysisBiotechnologyCureVac SE
Dec 2, 202512,488,173Methods and systems for training a neural network using sequential Monte Carlo processingComputer technologyInsta Deep Ltd
Nov 4, 202512,460,204Artificial nucleic acid molecules for improved protein or peptide expressionPharmaceuticalsCureVac SE
Nov 4, 202512,460,198Method for reducing immunogenicity of RNABiotechnologyBioNTech SE
Oct 21, 202512,447,209Combination of vaccination and inhibition of the PD-1 pathwayPharmaceuticalsCureVac SE
Oct 14, 202512,442,005Artificial nucleic acid molecules for improved protein expressionPharmaceuticalsCureVac SE
Oct 7, 202512,433,911Preparation and storage of liposomal RNA formulations suitable for therapyPharmaceuticalsBioNTech SE
Sep 23, 202512,421,319Binding agents that bind OX40 (CD134) and method of use thereof to treat diseasePharmaceuticalsBioNTech SE
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388944IN VITRO TRANSCRIPTION TECHNOLOGIESBiotechnologyBioNTech SE
Dec 11, 20252025/0376724LINEAR DOUBLE STRANDED DNA COUPLED TO A SINGLE SUPPORT OR A TAG AND METHODS FOR PRODUCING SAID LINEAR DOUBLE STRANDED DNABiotechnologyCureVac SE
Dec 11, 20252025/0375534COMPLEXES FOR DELIVERY OF NUCLEIC ACIDSPharmaceuticalsBioNTech SE
Dec 4, 20252025/0367320RNA Particles Comprising PolysarcosinePharmaceuticalsBioNTech SE
Dec 4, 20252025/0367275METHODS OF TREATING PANCREATIC CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINEPharmaceuticalsBioNTech SE
Nov 27, 20252025/0360196COMBINATION VACCINEPharmaceuticalsCureVac SE
Nov 20, 20252025/0352636NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGENPharmaceuticalsCureVac SE
Nov 13, 20252025/0345524SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNAMedical technologyCureVac SE
Nov 13, 20252025/0345417COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMAPharmaceuticalsBioNTech SE
Nov 13, 20252025/0345416PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS ANTIGENS AND RELATED METHODSPharmaceuticalsBioNTech SE
What it applied for, 2024 to 2025: Pharmaceuticals 108 · Biotechnology 27 · Computer technology 7 · Medical technology 5 · Organic fine chemistry 4 · Measurement 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BNTX · research, not advice